In contrast, CTLA-4 monotherapy rarely precipitates diabetes, potentially reflecting both narrower clinical utilization and the constitutive expression of CTLA-4 in pituitary tissue, which may bias toxicity toward hypophysitis rather than pancreatic autoimmunity (17). Here, CTLA4 is linked to autoimmune pancreatitis.